v3.26.3
SEGMENT INFORMATION (Tables)
9 Months Ended
Sep. 30, 2026
SEGMENT INFORMATION  
Schedule of segment reportable segments

By Business Unit

 

Provision for genomic screening services

 

 

Trading of industrial chemicals

 

 

Investment holding

 

 

Total

 

 

 

Nine-month periods ended September 30, 2026

 

 

 

 

 

 

 

 

 

 

 

 

 

 

REVENUE

 

$1,961

 

 

$144,954

 

 

$-

 

 

$146,915

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

COST OF REVENUE

 

 

(1,250)

 

 

(128,985)

 

 

-

 

 

 

(130,235)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GROSS PROFIT

 

 

711

 

 

 

15,969

 

 

 

-

 

 

 

16,680

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OTHER INCOME

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

38,273

 

 

 

16,630

 

 

 

-

 

 

 

54,903

 

Gain from foreign exchange

 

 

8,227

 

 

 

1,790

 

 

 

48

 

 

 

10,065

 

Others

 

 

-

 

 

 

22,779

 

 

 

-

 

 

 

22,779

 

TOTAL OTHER INCOME

 

 

46,500

 

 

 

41,199

 

 

 

48

 

 

 

87,747

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OPERATING EXPENSES

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales and marketing

 

 

(98,154)

 

 

(2,790)

 

 

(22,818)

 

 

(123,762)

Research and development

 

 

(41,736)

 

 

-

 

 

 

-

 

 

 

(41,736)

General and administrative

 

 

(180,877)

 

 

(162,031)

 

 

(600,034)

 

 

(942,942)

Provision for credit losses, net

 

 

-

 

 

 

(76,814)

 

 

-

 

 

 

(76,814)

Share-based compensation

 

 

-

 

 

 

-

 

 

 

(799,998)

 

 

(799,998)

TOTAL OPERATING EXPENSES

 

 

(320,767)

 

 

(241,635)

 

 

(1,422,850)

 

 

(1,985,252)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

LOSS FROM OPERATIONS

 

 

(273,556)

 

 

(184,467)

 

 

(1,422,802)

 

 

(1,880,825)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

FINANCE COSTS

 

 

-

 

 

 

(1,574)

 

 

(2,007)

 

 

(3,581)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

LOSS BEFORE TAX

 

 

(273,556)

 

 

(186,041)

 

 

(1,424,809)

 

 

(1,884,406)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Tax expense

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS

 

$(273,556)

 

$(186,041)

 

$(1,424,809)

 

$(1,884,406)

 

 

Provision for

 

 

 

 

 

 

 

 

 

 

 

 

genomic

 

 

Trading of

 

 

 

 

 

 

 

 

 

screening

 

 

industrial

 

 

Investment

 

 

 

 

 

 

services

 

 

chemicals

 

 

holding

 

 

Total

 

 

 

Nine months period ended September 30, 2025

 

 

 

 

 

 

 

 

 

 

 

 

 

 

REVENUE

 

$11,302

 

 

$6,929,849

 

 

$-

 

 

$6,941,151

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

COST OF REVENUE

 

 

(4,995)

 

 

(5,846,956)

 

 

-

 

 

 

(5,851,951)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GROSS PROFIT

 

 

6,307

 

 

 

1,082,893

 

 

 

-

 

 

 

1,089,200

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OTHER INCOME

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Dividend income

 

 

-

 

 

 

21,752

 

 

 

-

 

 

 

21,752

 

Interest income

 

 

63,646

 

 

 

10,468

 

 

 

-

 

 

 

74,114

 

Fair value gain on investments in equity securities

 

 

-

 

 

 

28,256

 

 

 

-

 

 

 

28,256

 

Gain on disposal of investments in equity securities

 

 

-

 

 

 

42,376

 

 

 

-

 

 

 

42,376

 

Others

 

 

10,919

 

 

 

136,312

 

 

 

-

 

 

 

147,231

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

TOTAL OTHER INCOME

 

 

74,565

 

 

 

239,164

 

 

 

-

 

 

 

313,729

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OPERATING EXPENSES

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales and marketing

 

 

(86,275)

 

 

(1,577,214)

 

 

(37,202)

 

 

(1,700,691)

Research and development

 

 

(39,572)

 

 

-

 

 

 

-

 

 

 

(39,572)

General and administrative

 

 

(270,725)

 

 

(492,464)

 

 

(600,888)

 

 

(1,364,077)

Fair value loss on investments in equity securities

 

 

-

 

 

 

(119,499)

 

 

-

 

 

 

(119,499)

Provision for credit losses, net

 

 

-

 

 

 

(121,030)

 

 

-

 

 

 

(121,030)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

TOTAL OPERATING EXPENSES

 

 

(396,572)

 

 

(2,310,207)

 

 

(638,090)

 

 

(3,344,869)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

LOSS FROM OPERATIONS

 

 

(315,700)

 

 

(988,150)

 

 

(638,090)

 

 

(1,941,940)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

FINANCE COSTS

 

 

(32)

 

 

(6,266)

 

 

(252)

 

 

(6,550)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

LOSS BEFORE TAX

 

 

(315,732)

 

 

(994,416)

 

 

(638,342)

 

 

(1,948,490)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Tax expense

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS

 

$(315,732)

 

$(994,416)

 

$(638,342)

 

$(1,948,490)

By Country

 

Malaysia

 

 

United States

 

 

Total

 

 

 

Nine-month period ended September 30, 2026

 

 

 

 

 

 

 

 

 

 

 

REVENUE

 

$146,915

 

 

$-

 

 

$146,915

 

 

 

 

 

 

 

 

 

 

 

 

 

 

COST OF REVENUE

 

 

(130,235)

 

 

-

 

 

 

(130,235)

 

 

 

 

 

 

 

 

 

 

 

 

 

GROSS PROFIT

 

 

16,680

 

 

 

-

 

 

 

16,680

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OTHER INCOME

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

54,903

 

 

 

-

 

 

 

54,903

 

Gain from foreign exchange

 

 

10,017

 

 

 

48

 

 

 

10,065

 

Others

 

 

22,779

 

 

 

-

 

 

 

22,779

 

TOTAL OTHER INCOME

 

 

87,699

 

 

 

48

 

 

 

87,747

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OPERATING EXPENSES

 

 

 

 

 

 

 

 

 

 

 

 

Sales and marketing

 

 

(100,944)

 

 

(22,818)

 

 

(123,762)

Research and development

 

 

(41,736)

 

 

-

 

 

 

(41,736)

General and administrative

 

 

(342,908)

 

 

(600,034)

 

 

(942,942)

Provision for credit losses, net

 

 

(76,814)

 

 

-

 

 

 

(76,814)

Share-based compensation

 

 

-

 

 

 

(799,998)

 

 

(799,998)

TOTAL OPERATING EXPENSES

 

 

(562,402)

 

 

(1,422,850)

 

 

(1,985,252)

 

 

 

 

 

 

 

 

 

 

 

 

 

LOSS FROM OPERATIONS

 

 

(458,023)

 

 

(1,422,802)

 

 

(1,880,825)

 

 

 

 

 

 

 

 

 

 

 

 

 

FINANCE COSTS

 

 

(1,574)

 

 

(2,007)

 

 

(3,581)

 

 

 

 

 

 

 

 

 

 

 

 

 

LOSS BEFORE TAX

 

 

(459,597)

 

 

(1,424,809)

 

 

(1,884,406)

 

 

 

 

 

 

 

 

 

 

 

 

 

Tax expense

 

 

-

 

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS

 

$(459,597)

 

$(1,424,809)

 

$(1,884,406)

By Country

 

Malaysia

 

 

United States

 

 

Total

 

 

 

Nine-month period ended September 30, 2025

 

 

 

 

 

 

 

 

 

 

 

REVENUE

 

$6,941,151

 

 

$-

 

 

$6,941,151

 

 

 

 

 

 

 

 

 

 

 

 

 

 

COST OF REVENUE

 

 

(5,851,951)

 

 

-

 

 

 

(5,851,951)

 

 

 

 

 

 

 

 

 

 

 

 

 

GROSS PROFIT

 

 

1,089,200

 

 

 

-

 

 

 

1,089,200

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OTHER INCOME

 

 

 

 

 

 

 

 

 

 

 

 

Dividend income

 

 

21,752

 

 

 

-

 

 

 

21,752

 

Interest income

 

 

74,114

 

 

 

-

 

 

 

74,114

 

Fair value gain on investments in equity securities

 

 

28,256

 

 

 

-

 

 

 

28,256

 

Gain on disposal of investments in equity securities

 

 

42,376

 

 

 

-

 

 

 

42,376

 

Others

 

 

147,231

 

 

 

 

 

 

 147,231

 

TOTAL OTHER INCOME

 

 

313,729

 

 

 

-

 

 

 

313,729

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OPERATING EXPENSES

 

 

 

 

 

 

 

 

 

 

 

 

Sales and marketing

 

 

(1,663,489)

 

 

(37,202)

 

 

(1,700,691)

Research and development

 

 

(39,572)

 

 

-

 

 

 

(39,572)

General and administrative

 

 

(763,189)

 

 

(600,888)

 

 

(1,364,077)

Fair value loss on investments in equity securities

 

 

(119,499)

 

 

-

 

 

 

(119,499)

Provision for credit losses, net

 

 

(121,030)

 

 

-

 

 

 

(121,030)

TOTAL OPERATING EXPENSES

 

 

(2,706,779)

 

 

(638,090)

 

 

(3,344,869)

 

 

 

 

 

 

 

 

 

 

 

 

 

LOSS FROM OPERATIONS

 

 

(1,303,850)

 

 

(638,090)

 

 

(1,941,940)

 

 

 

 

 

 

 

 

 

 

 

 

 

FINANCE COSTS

 

 

(6,298)

 

 

(252)

 

 

(6,550)

 

 

 

 

 

 

 

 

 

 

 

 

 

LOSS BEFORE TAX

 

 

(1,310,148)

 

 

(638,342)

 

 

(1,948,490)

 

 

 

 

 

 

 

 

 

 

 

 

 

Tax expense

 

 

-

 

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS

 

$(1,310,148)

 

$(638,342)

 

$(1,948,490)

 

 

Provision for genomic screening services

 

 

Trading of industrial chemicals

 

 

Investment holding

 

 

Total

 

 

 

As of September 30, 2026

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Segment assets

 

$1,643,808

 

 

$4,250,922

 

 

$2,865,971

 

 

$8,760,701

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Included in the measure of segment assets are:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Addition to non-current assets other than financial instruments and deferred tax assets

 

 

163

 

 

 

78,323

 

 

 

-

 

 

 

78,486

 

 

 

Provision for genomic screening services

 

 

Trading of industrial chemicals

 

 

Investment holding

 

 

Total

 

 

 

As of December 31, 2025

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Segment assets

 

$2,281,947

 

 

$4,577,690

 

 

$2,393,147

 

 

$9,252,784

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Included in the measure of segment assets are:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Addition to non-current assets other than financial instruments and deferred tax assets

 

 

1,382

 

 

 

35,589

 

 

 

-

 

 

 

36,971